Unit 4: Advances in Molecular Biology & Genetics

Molecular biology and genetics form one of the most active "thrust" research areas in the life sciences, concerned with how genetic information is stored, copied, expressed and manipulated at the level of DNA, RNA and protein. This unit orients a dissertation-stage researcher toward the current frontiers of the field, the enabling technologies, and the way problems are framed and pursued in modern laboratories.

• Central dogma: the framework the whole field rests on — DNA → RNA → protein, with transcription and translation as the two information-transfer steps and reverse transcription (RNA → DNA) as the noted exception in retroviruses.
• Gene: a segment of DNA encoding a functional product (polypeptide or functional RNA), defined by promoter, coding sequence, and regulatory elements.
• Genome: the complete set of genetic material in a cell (~3.2 billion base pairs in humans, ~20,000 protein-coding genes).
• Model systems: E. coli, Saccharomyces cerevisiae, Drosophila melanogaster, Caenorhabditis elegans, Mus musculus, and Arabidopsis thaliana, chosen for short generation time and genetic tractability.
• Working conventions: sequences written 5′→3′; genes italicised, proteins in roman; base pairing A–T, G–C.

II. Thrust Research Areas in Molecular Biology and Genetics

The domains where dissertation-level effort concentrates today.

A. Genome Sequencing and Analysis

Reading complete genomes has shifted the field from single-gene study to genome-wide inquiry.

• Sanger sequencing: chain-termination method using dideoxynucleotides (ddNTPs); accurate to ~700–900 bp per read, still the reference standard for short verification.
• Next-generation sequencing (NGS): massively parallel short-read platforms (Illumina) generating gigabases per run at low cost per base; underpins whole-genome and whole-exome studies.
• Third-generation sequencing: single-molecule long reads (Oxford Nanopore, PacBio) reading 10–100 kb, resolving repeats and structural variants that short reads miss.
• Comparative and functional genomics: aligning genomes across species to infer conserved (hence functional) regions; the ENCODE project mapped regulatory elements across the human genome.

B. Recombinant DNA Technology

Cutting, joining and propagating DNA in vitro is the enabling toolkit of the entire discipline.

• Restriction enzymes: bacterial endonucleases cutting at palindromic sites — e.g. EcoRI recognises GAATTC and cleaves between G and A, leaving sticky ends.
• Vectors: plasmids, bacteriophage, cosmids and BACs carry inserts into host cells; features include an origin of replication, selectable marker (antibiotic resistance) and multiple cloning site.
• Ligation and transformation: DNA ligase seals inserts into vectors; recombinant plasmids are taken up by competent E. coli and selected on antibiotic plates.
• Application: industrial production of recombinant human insulin (Humulin, 1982) — the first FDA-approved recombinant drug.

C. Polymerase Chain Reaction and Amplification

PCR enables exponential amplification of a target DNA sequence from minute starting amounts.

• Reaction cycle: three temperature steps repeated 25–35 times —
  • Denaturation: ~94–95 °C separates the double strand.
  • Annealing: ~50–65 °C lets primers bind flanking sequences.
  • Extension: ~72 °C, Taq polymerase synthesises new strands.
• Amplification kinetics: copies grow as 2ⁿ.

Yield ≈ N₀ × 2ⁿ
N₀ = initial template copies
n  = number of cycles

• Variants: quantitative real-time PCR (qPCR) measures product accumulation live via fluorescent dyes; reverse-transcription PCR (RT-PCR) amplifies from an RNA template after cDNA synthesis.
• Worked example: starting from 10 template molecules, after 30 cycles the theoretical yield is 10 × 2³⁰ ≈ 1.07 × 10¹⁰ copies.

D. Gene Expression Analysis

Measuring which genes are active, when, and how strongly, links genotype to phenotype.

• Transcriptomics: RNA-Seq quantifies the entire transcript pool; expression reported in normalised units (TPM/FPKM) so genes of different length are comparable.
• Microarrays: hybridisation of labelled cDNA to fixed probes; largely superseded by RNA-Seq but still used for fixed-content panels.
• Regulation studied: promoters, enhancers, transcription factors, and alternative splicing that lets one gene yield multiple protein isoforms.
• Reporter assays: fusing a gene's promoter to GFP or luciferase reveals expression timing and localisation in vivo.

E. Genome Editing Technologies

Precise, programmable modification of endogenous sequences is the field's most transformative recent thrust.

Two generations of tools contrast in targeting mechanism:

1. Protein-guided nucleases (ZFNs, TALENs): DNA-binding protein domains fused to the FokI nuclease; specificity re-engineered protein by protein, making them laborious to retarget.
2. RNA-guided CRISPR-Cas9: a single guide RNA (sgRNA) directs Cas9 to a complementary 20-nt sequence next to a PAM (NGG for S. pyogenes Cas9); retargeting needs only a new 20-nt guide, so it is fast and cheap.

• Repair outcomes: the double-strand break is resolved by non-homologous end joining (NHEJ, error-prone, used for knockouts) or homology-directed repair (HDR, precise, used for knock-ins with a donor template).
• Refinements: base editors convert single bases (C→T, A→G) without a double-strand break; prime editing writes short defined edits via a reverse-transcriptase–Cas9 fusion.
• Recognition: the 2020 Nobel Prize in Chemistry (Charpentier and Doudna) for CRISPR-Cas9 gene editing.

F. Functional Genetics and Gene Silencing

Turning genes off is as informative as reading them for assigning function.

• RNA interference (RNAi): double-stranded RNA is processed by Dicer into ~21-nt siRNAs that guide the RISC complex to degrade complementary mRNA.
• microRNAs (miRNAs): endogenous ~22-nt regulators that repress translation of partially complementary targets.
• Knockout vs knockdown:
  • Knockout: permanent gene disruption in the genome (e.g. CRISPR-generated null allele).
  • Knockdown: transient reduction of transcript level (e.g. siRNA transfection).
• Antisense oligonucleotides: short synthetic strands blocking translation or altering splicing — basis of drugs such as nusinersen for spinal muscular atrophy.

G. Structural and Systems Approaches

The field increasingly integrates molecular parts into whole-network and structural models.

• Structural biology: X-ray crystallography, cryo-electron microscopy and, computationally, AlphaFold, which predicts protein 3-D structure from amino-acid sequence.
• Proteomics: mass-spectrometry–based identification and quantification of the full protein complement of a cell.
• Systems biology: modelling gene-regulatory and metabolic networks rather than single pathways, using high-throughput "omics" data integrated computationally.
• Bioinformatics backbone: sequence alignment (BLAST), databases (GenBank, UniProt, Ensembl) and statistical pipelines that make large datasets interpretable.

III. Applications of the Thrust Area

Where molecular and genetic research delivers real-world impact.

A. Medical and Diagnostic Applications

Molecular tools have reshaped how disease is detected and treated.

• Molecular diagnostics: PCR- and sequencing-based detection of pathogens and mutations — RT-PCR was the reference SARS-CoV-2 test.
• Gene therapy: delivering functional genes via viral vectors (AAV, lentivirus); Luxturna (2017) treats inherited retinal dystrophy.
• Pharmacogenomics: tailoring drug choice and dose to a patient's genotype (e.g. CYP2C19 variants affecting clopidogrel metabolism).
• Cancer genomics: identifying driver mutations to guide targeted therapy (e.g. HER2 amplification and trastuzumab).

B. Agricultural and Industrial Applications

Genetic technology extends beyond medicine into crops and bioprocessing.

• Transgenic crops: Bt cotton and maize carry a Bacillus thuringiensis gene conferring insect resistance; Golden Rice engineered to synthesise β-carotene.
• CRISPR crops: targeted edits for drought tolerance and disease resistance without foreign DNA integration.
• Industrial biotechnology: engineered microbes producing enzymes, biofuels and pharmaceuticals through metabolic engineering.

C. Ethical and Regulatory Dimensions

Power over the genome brings responsibilities the dissertation researcher must address.

• Germline editing: heritable human editing is widely restricted; the 2018 edited-embryo case drew global condemnation and prompted moratorium calls.
• Data privacy: genomic data is uniquely identifying, raising consent and confidentiality concerns.
• Biosafety and dual-use: containment of genetically modified organisms and oversight of gain-of-function research.

IV. Framing a Dissertation in This Thrust Area

Turning the field into a researchable project.

A. Identifying the Research Gap

A dissertation begins by locating an unanswered, tractable question.

• Literature survey: systematic reading of recent primary papers to map what is known and what remains open.
• Gap statement: a specific limitation — an unexplained phenotype, an uncharacterised gene, an untested regulatory link.
• Feasibility: matching the question to available techniques, model systems, time and budget.

B. Hypothesis and Experimental Design

Rigour depends on a testable hypothesis and controlled design.

• Hypothesis: a falsifiable statement, e.g. "knockdown of gene X reduces proliferation in cell line Y."
• Controls: positive, negative and vehicle controls to isolate the variable of interest.
• Replication and statistics: biological and technical replicates with appropriate tests (t-test, ANOVA) to establish significance (typically p < 0.05).

C. Reproducibility and Reporting

Credible molecular research is transparent and repeatable.

• Standards: MIQE guidelines for qPCR reporting; deposition of sequence data in public repositories (SRA, GEO).
• Documentation: detailed protocols, reagent catalogue numbers and version-controlled analysis code so results can be independently verified.